I reported previously (see here) on the NeuroAD cranial device from Israel’s Neuronix. It already has European approval and is now being urgently reviewed in the FDA’s Expedited Access Pathway program for breakthrough devices that target vital unmet needs. https://www.medpagetoday.com/neurology/alzheimersdisease/78739

In latest trials, the NeuroAD cranial device from Israel’s Neuronix (see here) slowed the progression of the disease in 85% of patients suffering mild Alzheimer’s.  The treatment is now being used commercially in the UK (London, Berkshire, Chester and Manchester). … Continue reading →

I reported previously on the neuroAD transcranial magnetic stimulation (TMS) and cognitive training from Israel’s Neuronix (see here). NeuroAD now has CE approval and is commercially available in Israel, Europe and Asia. US FDA approval is subject to results of … Continue reading →

In Harvard’s clinical trial, the NeuroAD system from Israel’s Neuronix not only stopped patients’ symptoms from deteriorating, in some cases it actually improved patients’ cognitive performance to a greater extent than what is currently available with approved medications. http://www.prnewswire.com/news-releases/computer-exercises-may-offer-new-hope-for-alzheimers-patients-170678416.html